- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05087693
Salbutamol Use in Ozone Air Pollution by People With Asthma and/or Exercise Induced Bronchoconstriction (EIB)
February 26, 2025 updated by: Michael Koehle, University of British Columbia
Examining the Effect of Salbutamol Use in Asthma and/or Exercise Induced Bronchoconstriction Whilst Exercising in Ozone Air Pollution
Salbutamol use is increased in areas with high levels of ozone pollution and the potential consequences of this are not well known.
The purpose of this study is to examine the effect of salbutamol on lung function and inflammation in people with asthma and/or EIB exercising in ozone air pollution.
To examine this, we are planning a randomized cross over trial where people with asthma and/or EIB complete sub maximal exercise in four conditions on four separate days.
The four condition are: ozone + salbutamol, filtered air + salbutamol, ozone + placebo medication, and filtered air + placebo medication.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
18
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V6T 1Z1
- Environmental Physiology Laboratory
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 50 years (Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Have asthma and/or EIB
- Able to perform maximal exercise
- Able to communicate sufficiently using the English language
Exclusion Criteria:
- Allergic to salbutamol (also known as Ventolin)
- Pregnant or potentially pregnant
- Have a history of smoking
- Had an upper respiratory tract infection within the last 4 weeks
- Have a chronic respiratory disease other than asthma or EIB
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Exercising in ozone following salbutamol inhalation
Participants will be doing sub-maximal exercise (60% of VO2max for 30 minutes) on a cycle ergometer while inhaling 170ppb ozone after inhaling 200ug of salbutamol.
|
Inhaling 200ug of salbutamol
Breathing 170ppb ozone
Cycling at 60% of VO2max on a cycle ergometer
|
|
Active Comparator: Exercising in filtered air following salbutamol inhalation
Participants will be doing sub-maximal exercise (60% of VO2max for 30 minutes) on a cycle ergometer while inhaling filtered air after inhaling 200ug of salbutamol.
|
Inhaling 200ug of salbutamol
Cycling at 60% of VO2max on a cycle ergometer
Breathing filtered air
|
|
Placebo Comparator: Exercising in ozone following placebo inhalation
Participants will be doing sub-maximal exercise (60% of VO2max for 30 minutes) on a cycle ergometer while inhaling 170ppb ozone after inhaling placebo medication.
|
Breathing 170ppb ozone
Cycling at 60% of VO2max on a cycle ergometer
Inhaling placebo medication
|
|
Placebo Comparator: Exercising in filtered air following placebo inhalation
Participants will be doing sub-maximal exercise (60% of VO2max for 30 minutes) on a cycle ergometer while inhaling filtered after inhaling placebo medication.
|
Cycling at 60% of VO2max on a cycle ergometer
Breathing filtered air
Inhaling placebo medication
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Measured Before and 30 Minutes After Exercise in Each 1 Day Condition
Time Frame: Measured before and 30 minutes after exercise in each 1 day condition
|
Measure of pulmonary function
|
Measured before and 30 minutes after exercise in each 1 day condition
|
|
Change in FVC From Baseline to 30 Minutes After Exercise
Time Frame: Measured before and 30 minutes after exercise in each 1 day condition
|
Measure of pulmonary function
|
Measured before and 30 minutes after exercise in each 1 day condition
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 1, 2021
Primary Completion (Actual)
August 31, 2023
Study Completion (Actual)
August 31, 2023
Study Registration Dates
First Submitted
September 28, 2021
First Submitted That Met QC Criteria
October 8, 2021
First Posted (Actual)
October 21, 2021
Study Record Updates
Last Update Posted (Actual)
March 25, 2025
Last Update Submitted That Met QC Criteria
February 26, 2025
Last Verified
February 1, 2025
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Immune System Diseases
- Respiratory Tract Diseases
- Lung Diseases
- Bronchial Diseases
- Lung Diseases, Obstructive
- Respiratory Hypersensitivity
- Hypersensitivity, Immediate
- Hypersensitivity
- Asthma
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Reproductive Control Agents
- Neurotransmitter Agents
- Adrenergic Agonists
- Adrenergic Agents
- Respiratory System Agents
- Anti-Asthmatic Agents
- Bronchodilator Agents
- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta-Agonists
- Tocolytic Agents
- Albuterol
Other Study ID Numbers
- H21-01080
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Any data shared will not contain any personal identifiers.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma and/or Exercise Induced Bronchoconstriction
-
Teva Branded Pharmaceutical Products R&D, Inc.CompletedExercise-Induced Bronchoconstriction (EIB)United States
-
Norwegian University of Science and TechnologyKlinikk for allergi og luftveissykdommerCompletedExercise Induced BronchoconstrictionNorway
-
Universitaire Ziekenhuizen KU LeuvenJessa Hospital; Algemeen Ziekenhuis Maria MiddelaresCompletedAdolescent | Biomarker | Exercise Induced Bronchoconstriction | Young AthletesBelgium
-
Medisch Spectrum TwenteHaukeland University HospitalNot yet recruitingAsthma in Children | Larynx | Dyspnea | Exercise-Induced Bronchoconstriction | Exercise-Induced Bronchospasm | Exercise Induced Laryngeal ObstructionNetherlands
-
Universitaire Ziekenhuizen KU LeuvenJessa Hospital; Algemeen Ziekenhuis Maria MiddelaresTerminatedExercise-Induced BronchoconstrictionBelgium
-
Organon and CoCompletedExercise-induced Bronchoconstriction (EIB)
-
Karolinska InstitutetNorwegian School of Sport Sciences; Olympiatoppen, The Norwegian Olympic Sports...CompletedAsthma | Exercise Induced BronchoconstrictionNorway
-
University of British ColumbiaNatural Sciences and Engineering Research Council, Canada; Canadian Academy... and other collaboratorsCompletedAir Pollution | Exercise-induced BronchoconstrictionCanada
-
Johann Wolfgang Goethe University HospitalCompleted
-
Indiana UniversityPharmalinkCompletedAsthma | Exercise-Induced BronchoconstrictionUnited States
Clinical Trials on Salbutamol
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Canisius-Wilhelmina HospitalRecruitingAsthma in Children | Agents, Anti AsthmaticNetherlands
-
King Abdullah University HospitalJordan University of Science and TechnologyNot yet recruitingDiabete Mellitus | Atelectases, Postoperative PulmonaryJordan
-
Vastra Gotaland RegionCompletedMusculoskeletal Diseases | Neuromuscular Diseases | Centronuclear Myopathy | Nemaline Myopathy | Congenital Myopathy | Myosin Storage MyopathySweden
-
Chiesi Farmaceutici S.p.A.CompletedBronchial AsthmaSpain, Italy, Russian Federation, Ukraine
-
Shanghai Ninth People's Hospital Affiliated to...UnknownAdenoid Cystic CarcinomaChina
-
Assistance Publique - Hôpitaux de ParisURC-CIC Paris Descartes Necker CochinTerminated
-
Boehringer IngelheimCompletedPulmonary Disease, Chronic Obstructive
-
Research in Real-Life LtdTeva Branded Pharmaceutical Products R&D, Inc.CompletedAsthmaUnited Kingdom